Eli Lilly Introduced First-of-its-kind Kisunla™ for Alzheimer's Disease
Eli Lilly has launched Kisunla™ (donanemab-azbt), a groundbreaking therapy for adults with early symptomatic Alzheimer's disease (AD), encompassing those with mild cognitive impairment (MCI) and mild dementia stages with confirmed amyloid pathology.
Kisunla marks as the first treatment targeting amyloid plaques with a regimen designed for short-term therapy focused on reducing amyloid plaque levels. Nearly half of the participants successfully completed their 12-month treatment course with Kisunla.
Kisunla is administered via intravenous (IV) infusion through a needle placed in a vein in the arm. It is given once every 4 weeks, with each infusion lasting approximately 30 minutes.
This therapy aids in removing excessive amyloid plaques, potentially slowing the progression that affects memory, planning, organisation, meal preparation, appliance use, and independence.
Significant findings from Kisunla trials indicate a marked slowdown in clinical decline among early symptomatic AD patients. In less advanced stages, Kisunla reduced decline by 35 percent compared to placebo on the integrated alzheimer's disease rating scale (iADRS), which evaluates memory, cognition, and daily function.
The FDA has approved Kisunla™ (donanemab-azbt), administered as a 350 mg/20 mL once-monthly IV infusion, for adults experiencing early symptomatic Alzheimer's disease (AD).
